Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug SubstanceAgreement covers contract development and manufacturing of lead compound PH-762July 25, 2025 7:45 AM EDT | Source: Phio Pharmaceuticals Corp.King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio  ...